The patient who was hospitalized after receiving Intellia Therapeutics’ CRISPR therapy nex-z has died. | The patient who was ...

Shares in gene-editing specialist Intellia Therapeutics came under renewed pressure today after a patient in one of its ...

The FDA previously placed two clinical studies on hold, including the Phase III trial in which the liver toxicity occurred.

Explore CRISPR technology explained, gene editing science, DNA modification, and genetic engineering ethics—discover how ...

Technology opens the door to more accurate preclinical testing, which could enable the development of safer and more effective therapies.

Many plants including cocoa, coffee and avocado cannot be gene-edited but a technique involving grafting could change that, ...

A poorly characterized protein, historically thought to be a chaperon or enzyme, may actually be a key player in prostate ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of ...

Comprehensive TK-6302 data demonstrate preclinical efficacy and safety, supporting clinical readiness, alongside established ...

Intellia Therapeutics (NTLA) stock plummets after the company's Q3 updates indicate a patient deeath in a Phase 3 for its nex ...

Our round-up of biotech financings is led this week by Braveheart Bio, a San Francisco biotech that has launched with $185 ...